StockData

Liminatus Pharma, Inc. (LIMNW) stock

LIMNWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as LIMN
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 2/30
$0.04+0.00 (0.00%)

Close on Oct 30, 2026Market cap $189.39MP/E –Yield –

Earnings

Liminatus Pharma's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Liminatus Pharma's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Liminatus Pharma has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Liminatus Pharma puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Liminatus Pharma filed with the SEC as exhibits to Form 8-K or 6-K

  1. Liminatus Pharma Regains Compliance with Nasdaq
    Update
  2. Liminatus Pharma, Inc. Announces Reverse Stock
    Update
  3. Liminatus Pharma Enters Into Warrant Exercise
    News
  4. Liminatus Pharma, Inc. Announces Pricing of
    News
  5. IBA101: The Strategic Answer to the PD-1/L1 Patent Cliff
    Update
  6. Liminatus Pharma Charts Dual-Front Attack on
    Update
  7. Crafting the Future of Healing for Patients Next Generation CD47 Blockade with Liminatus Pharma, Innobation Bio
    News
  8. Liminatus Pharma, the newest immuno-oncology entrant on Nasdaq (ticker:
    News
  9. To the Board of Directors and Stockholder of
    Update
  10. To the Board of Directors, Stockholders, and Members
    Update
  11. 8-K exhibit EX-99.3
    Update